Daigle Barbara J, Rekkerth Donna J
Eastern Maine Otolaryngology, Bangor, Maine, USA.
Allergy Rhinol (Providence). 2015 Jan;6(1):1-7. doi: 10.2500/ar.2015.6.0111.
Critical aspects of formulating allergy immunotherapy vaccines include the selection, total number, and proportions of each allergen component in therapeutic mixtures. The immunotherapy prescription, determined by a medical provider, details the dosing and schedule for treatment as well as the specific composition of the treatment vials. Allergen extracts are composed of many components such as proteins, glycoproteins, and proteases. Some components in allergen extracts are cross-reactive, meaning that treatment with an extract from one species may confer partial protection against a triggering allergen from another species. Conversely, some allergen extracts are incompatible with other extracts when combined in a mixture for treatment, resulting in lowered therapeutic potential for the patient. Therefore, knowledge of allergen extract cross-reactivities and incompatibilities guides the preparation of subcutaneous immunotherapy prescriptions. In a clinical setting, an understanding of what can and can not be mixed is one critical element in improving treatment outcomes.
制定过敏免疫疗法疫苗的关键方面包括治疗混合物中每种过敏原成分的选择、总数和比例。由医疗服务提供者确定的免疫疗法处方详细说明了治疗的剂量和时间表以及治疗小瓶的具体成分。过敏原提取物由许多成分组成,如蛋白质、糖蛋白和蛋白酶。过敏原提取物中的一些成分具有交叉反应性,这意味着用一种物种的提取物进行治疗可能会对另一种物种的触发过敏原提供部分保护。相反,当某些过敏原提取物在混合用于治疗时与其他提取物不相容,会导致患者的治疗潜力降低。因此,了解过敏原提取物的交叉反应性和不相容性有助于指导皮下免疫疗法处方的制定。在临床环境中,了解哪些可以混合哪些不可以混合是改善治疗效果的一个关键因素。